23andme to obtain Regeneron

DNA test company 23andme (UnhappyIt is purchased from bankruptcy by the major drug maker Regerron (rain), For $ 256 million.

The deal includes “all the assets largely”, but it excludes a remote health care platform, pharmaceutical loyalty, laboratory and testing services under Lemonaid Health, according to the agreement submitted in the American Banking Court in the eastern province of Missouri. The deal is scheduled to be closed on July 1.

The news sent 23ndme shares to more than 26 % in the pre -market trade. Regeneron shares increased slightly over 1 %.

The sharp discount on a high -value test company sets concerns about the fate of sensitive genetic data for millions of customers. It is also in line with a strategy that was 23andme for a year.

“Regeneron intends to obtain the personal genome service for 23andme (PGS), and the total health and research services lines, as well as biological banks and associated assets, for $ 256 million and 23 and 23 years, and all the gym consumer services continue in the third quarter of 2025”.

23andme, which was launched in 2006, was famous Leadership and participated in its founding -The former wife of Google Breen’s founder. The company was For 10 years I tried to create a strong business sector Its DNA pair with the discovery of drugs – hoping that it will make it more efficient as the industry has turned into more customized and targeted treatments. But the few The partnerships that have succeeded in securing over the years I produced a little.

Regerron is already linking the non -specific genetic data to the discovery of drugs, according to the co -founder and chairman George Yankopoulos.

“We have a widely deep data management experience, after they worked with collaborators all over the world to connect the specified DNA sequence of three million participants approved by electronic health records, safely and safely enabling medical developments in the future. He said in a statement on Monday,” He treats and prevents the disease in general. “

23ndme began closing clinical trials in November last year, and she fought in March.